Breaking News

Alexion Initiates Recall for Certain Lots of Soliris

June 2, 2014

The presence of visible particles were detected

Alexion Pharmaceuticals, Inc. is initiating a voluntary recall of certain lots of Soliris (eculizumab) 300 mg/30 mL concentrated solution for intravenous infusion, due to the presence of visible particles detected in a single lot during periodic stability testing. This lot was only distributed in the U.S., and, to date, there have been no product complaints of particulates, or identifiable safety concerns attributed to the product consumed from the affected lots.   
 
The lots were manufactured using a process component during vial filling identified in the November 2013 recall to the hospital/user level. The company believes it has identified the process component that resulted in the presence of the particles and implemented a change to the process. Alexion does not anticipate any interruption to patient supply.  
 
Following the recall, there will no longer be Soliris in the U.S. manufactured using the previously identified process component that Alexion believes resulted in the stability failure.
 
The administration of particulate, if present in a parenteral drug, poses a potential safety risk to patients in the form of an immune reaction and blood clots, which could be life-threatening.  
 
Soliris is approved as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two ultra-rare and life-threatening disorders.
 
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks